Navigation Links
Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
Date:10/1/2008

ore as fat by mimicking the effects of naturally occurring hormones. Amylin's approach has the potential to achieve significant weight loss with a reduced risk for side effects that are often seen with other obesity treatments."

KEY AMYLIN ACTIVITIES AT THE OBESITY SOCIETY MEETING

1. Invited symposium presentation: "Therapeutic Potential of Leptin in

General Obesity: A New, Integrated Neurohormonal Approach" will be

presented by Christian Weyer, MD, Vice President, Corporate

Development for Diabetes and Obesity at Amylin Pharmaceuticals, Inc.,

as part of a symposium entitled "Leptin: From Bench to Bedside" on

Sunday, October 5 from 3:45-5:30 p.m. PT (6:45 p.m. ET). This

symposium is part of the conference's core scientific program.

2. Oral 64-OR: "Enhanced weight loss following pramlintide/metreleptin

combination treatment in overweight and obese subjects is accompanied

by improved control of eating" will be presented by Steve Smith, MD,

Sunday, October 5 at 11:45 a.m. PT (2:45 p.m. ET).

3. Poster 323-P: "Safety of 360 ug pramlintide BID treatment for up to 2

years" will be presented by Nicole Kesty, PhD, Saturday, October 4 at

5 p.m. PT (8 p.m. ET).

4. Poster 592-P: "Changes in weight and binge eating scale scores in

obese subjects treated with pramlintide as monotherapy and in

combination with oral weight loss agents" will be presented by Fulton

Velez, MD, Sunday, October 5 at 5:30 p.m. PT (8:30 p.m. ET).

5. Poster 205-P: "Effects of amylin/leptin lead-in on the weight-reducing

effects of amylin and/or leptin in diet-induced obese (DIO) rats" will

be presented by Chunli Lei, Saturday, October 4 at 5 p.m. PT

(8 p.m. ET).

6. Poster 651-P: "AC2307, an amylin mimetic, reduced 24-h food intake in

obese subjects without changing sub
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Transcept Pharmaceuticals Submits New Drug Application for Intermezzo(R) for Treatment of Middle-of-the-Night Awakenings
3. Critical Pharmaceuticals Enter Sustained Release hGH Arena
4. Anadys Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
5. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
6. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
7. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
8. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Acute Coronary Syndrome (ACS) Trial
9. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
10. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
11. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)..., EXTON,Pa.,Nov.23/PRNewswire/--BioTrendsRese...M): Feraheme report,thesecondinamulti-phasesyndi...snewIVironproduct,Feraheme,throughthefirstsixmonth...quantitativeinformationfrom50uniqueNephrologistsan...ssesstrialanduseofFeraheme,obstaclestouse,reasonst...
(Date:11/23/2009)..., WALTHAM,Mass.,Nov.23/PRNewswire/--ProteonTh...studyofitsleadproduct,PRT-201,inend-stagerenaldise...graft(AVG)creation.TheAVGstudyrepresentsProteon,ss...iouslyannouncingtheinitiationofaPhase1/2studyofPRT...sfistula(AVF)creationearlierthisyear.Proteonalsoan...
(Date:11/23/2009)..., SOUTHSANFRANCISCO,Calif.,Nov.23/PRNewswire-...cedthatDr.TedW.LoveandDr.DavidC.U,Prichardhaveagre...ionoftheproposedmergerbetweenAnesivaandArcionThera...ervotescheduledtotakeplaceatthepreviouslyannounced...ecember3,2009at9:00a.m.PSTat400OysterPoint,Suite10...
Breaking Medicine Technology:Reported Use of AMAG's Feraheme (ferumoxytol) Continues To Be Low, But a Number of Nephrologists Are 'On the Verge' of Use 2Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 3Brown professor continues debate over recovered memory 50995 1Brown professor continues debate over recovered memory 50995 2Providence Service Corporation Does Not Expect California Budget Issues to Materially Impact Its Business in the State 50992 1Providence Service Corporation Does Not Expect California Budget Issues to Materially Impact Its Business in the State 50992 2Fewer Shots Could Still Protect Kids From Pneumonia 50989 1Fewer Shots Could Still Protect Kids From Pneumonia 50989 2
... Risk Based on Clinical Data, Preventive Measur...WALTHAM, Mass., July 22 Interleukin Genetics,Inc....nhanced test report,format and information package...test is currently marketed under the brand name Ge...y. The new report will include quantified risk,inf...
...rd Clinical Trial,Service Unit and Epidemiological...generating results of the SEAS trial of ezetimibe ...results from the SHARP and,IMPROVE-IT trials of ez...the relevant regulatory authorities, independently...esting trials (SHARP and IMPROVE-IT) contain about...
Other Medicine Technology:Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 2Interleukin Genetics Launches Enhanced Heart Health Genetic Test Report Format 3Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 2Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe 3
(Date:11/23/2009)....G.Schwade,M.D.announcesthenewlyenhancedCyberKnife...CenterofMiami,( www.cyberknifemiami.com ). ,,...edintensedoseofradiationthatkillscancercellswithno...nlastfrom30minutestoonehour,andisusuallycompletedi...tCenterintheSoutheasternU.S.,theMiamifacilityhasle...
(Date:11/23/2009)... to treatment advances, study finds , , ...ntent of saliva changes as people age, and better ...simple test to diagnose and treat age-related dise...ins numerous proteins that play a role in digestio...ers are trying to find ways to use these proteins ...
(Date:11/23/2009)...the brain is regulated by a peptide known as C3a, ...into nerve cells and is also important for the mig..., reveals new research from the Sahlgrenska Academ...ugh the research has been carried out using mice a... for human beings, which could be given to patient...
(Date:11/23/2009)...partment of Agriculture (USDA) has awarded a two-y...rsity of Minnesota to complete sequencing the geno.... The funding will be used by the Turkey Genome Se...ing using next-generation sequencing platforms, as... functions in the final genome sequence by use of ...
(Date:11/23/2009)...Call/--AnnTaylorStoresCorp.announcedtodaythatitwil...sandGivingcampaign,aholidayfundraisingandawareness...armarksthethirdyearthatAnnTaylor,throughitsANNCARE...mpaignwhereweofferourshoppersanopportunitytohelpsa...hisholidayseason.ClientswhoshopatAnnTaylor,Loft,An...
Breaking Medicine News(10 mins):Health News:Turkey Genome Sequencing Consortium awarded $0.9 million from USDA 2Health News:Ann Taylor Stores Corp. Returns To St. Jude Children's Research Hospital's Thanks and Giving Campaign(R) For The Third Year 2
... of a chemotherapeutic drug for leukemia to a stan...rs to enhance the response of certain ovarian canc...y led by researchers in the Duke Comprehensive Can...d Deanna Teoh, M.D., a fellow in gynecologic oncol...
... help older adults stay sharp , , SUNDAY, ...(at least in a video game) is just one of many way...in memory. , In this case, a study found that old... the world, according to the American Geriatric So...
...recently released study led by Joseph A. Roscoe, P...the American Cancer Society and the National Cance...stbands are effective in reducing nausea associate... This all natural and easy to administer remedy is...
...therford Hospital, Inc., a QHR management client s...anagement client since 1994, were recently ranked ...n overall organizational performance by Thomson Re...entwood, Tenn. (PRWEB) April 18, 2009 -- Rutherfor...
... may lead to better detection and treatment , ...tive receptor found in certain pancreatic cancers ...disease. , A third of human pancreatic cancers l...tudies had noted as being active in some lung canc...
...rgy Awareness Month , , SATURDAY, April 18...e offered at more than 200 sites across the United...gy Awareness Month. , Adults and children with sym...any people don,t realize their breathing problem m...
Other Medicine News:Health News:Addition of dasatinib to standard chemo cocktail may enhance effect in certain ovarian cancers 2Health News:Relief Is Available for Cancer Patients Suffering from Radiation Therapy-Related Nausea 2Health News:Two QHR Management Clients Named to Thomson Reuters' 100 Top Hospitals Rutherford Hospital, Inc. and Wooster Community Hospital Honored for Performance Excellence 2Health News:Research Takes Aim at Pancreatic Cancer 2Health News:Group Urges Public to Take Free Asthma Tests in May 2
7.75mm diameter Corneal Trephine Blades
6.5mm diameter Corneal Trephine Blades
5.5mm diameter Corneal Trephine Blades
7.50mm Open Trephine Handle
Medicine Products: